Business update from pharmaceutical company developing deucrictibant for HAE
Key data on a potential new HAE prophylaxis treatment, called deucrictibant, is expected in the third quarter of 2026, while the application for a US license for the medicine’s use on demand is on track to take place in the first half of 2026, according to a business update from the pharmaceutical company Pharvaris.
The key updates provided were:
- Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026
- Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks remains on track in 1H2026
- Enrolment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of acquired angioedema due to C1INH deficiency attacks
Berndt Modig, Chief Executive Officer of Pharvaris, said: “In 2026, Pharvaris remains focused on execution across our late-stage programs, including reporting CHAPTER-3 data in the third quarter and enrolling in CREAATE, and on establishing our commercial infrastructure in preparation for the potential launch of deucrictibant IR. The growing published scientific evidence of deucrictibant’s potential as an end-to-end portfolio solution for bradykinin-mediated angioedema care supports our clinical, regulatory, and commercial strategies.”
(Source: Pharvaris)